BRIEF published on 08/11/2026 at 18:35, 20 hours 23 minutes ago Medincell at Piper Sandler CNS Symposium 2026 Investors Medincell BEPO Technology Piper Sandler CNS Symposium Prolonged Treatments
BRIEF published on 08/11/2026 at 18:35, 20 hours 23 minutes ago Medincell au Piper Sandler CNS Symposium 2026 Investisseurs Medincell Piper Sandler CNS Symposium BEPO Technologie Traitements Prolongés
PRESS RELEASE published on 08/11/2026 at 18:30, 20 hours 28 minutes ago Informations privilégiées / Autres communiqués Medincell participera au Piper Sandler CNS Symposium le 13 août 2026 avec le Dr Grace Kim, CSO, U.S. Finance. L'entreprise développe des traitements injectables à action prolongée pour divers domaines thérapeutiques Medincell Dr Grace Kim Action Prolongée Piper Sandler CNS Symposium Traitements Injectables
BRIEF published on 07/29/2026 at 13:29, 14 days 1 hour ago Medincell Partner Teva Reports Strong UZEDY® Sales Growth Net Sales Growth Revenue Outlook Schizophrenia Treatment Teva Pharmaceuticals Long-acting Injectable
BRIEF published on 07/29/2026 at 13:29, 14 days 1 hour ago Record sales for UZEDY® in the second quarter of 2026 Schizophrenia Teva Pharmaceuticals UZEDY Sales 2026 Forecast Medincell Royalties
BRIEF published on 07/29/2026 at 13:29, 14 days 1 hour ago Ventes record pour UZEDY® au deuxième trimestre 2026 Schizophrénie Teva Pharmaceuticals Ventes UZEDY Prévisions 2026 Royalties Medincell
BRIEF published on 07/29/2026 at 13:29, 14 days 1 hour ago Le partenaire de Medincell, Teva, annonce une forte croissance des ventes d'UZEDY® Croissance Des Ventes Nettes Traitement De La Schizophrénie Perspectives De Revenus Teva Pharmaceuticals Injectable À Action Prolongée
PRESS RELEASE published on 07/29/2026 at 13:24, 14 days 1 hour ago Inside Information / Other news releases Teva's UZEDY® achieves record Q2 net sales of $77M, up 43% YoY. Olanzapine LAI FDA action anticipated in Q4 2026. Medincell's innovative long-acting injectable treatments show promising results Record Sales Medincell Teva UZEDY Long-acting Injectable
PRESS RELEASE published on 07/29/2026 at 13:24, 14 days 1 hour ago Informations privilégiées / Autres communiqués Ventes record d'UZEDY® de 77 M$ au 2ème trimestre 2026 (+43% sur un an), Teva relève ses prévisions. Annonce sur les résultats de Teva : ir.tevapharm.com Schizophrénie Ventes Record Teva Pharmaceuticals UZEDY® Prévisions 2026
BRIEF published on 07/28/2026 at 20:26, 14 days 18 hours ago Publication of the 2025/2026 Universal Registration Document by Medincell Financial Report General Assembly CSR Registration Document Medincell
Published on 08/12/2026 at 14:45, 13 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 14:00, 58 minutes ago International Battery Metals Appoints Scott Colangelo to Board of Directors
Published on 08/12/2026 at 13:55, 1 hour 3 minutes ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Published on 08/12/2026 at 13:45, 1 hour 13 minutes ago Amarc Announces Geophysical Surveys Identifying Major New Sulphide Mineralized Systems Adjacent To The Aurora Porphyry Copper-Gold Discovery
Published on 08/12/2026 at 14:30, 28 minutes ago Iute Group Reports Unaudited 6M 2026 Results on 27 August 2026 – Invitation to Earnings Webcast/Call on the Same Day
Published on 08/12/2026 at 14:10, 48 minutes ago Pudu Robotics Launches PUDU ET1, an AI-Native Compact Scrubber-Dryer Robot for Small Commercial Spaces
Published on 08/12/2026 at 13:58, 1 hour ago EQS-Adhoc: Vitruvia Medical AG: Half yearly results as per June 30,2026
Published on 08/12/2026 at 13:38, 1 hour 19 minutes ago Nebius reports second quarter 2026 financial results
Published on 08/11/2026 at 17:45, 21 hours 13 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 21 hours 18 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 20 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 20 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
